Jenise C Wong1, Claire Boyle2, Linda A DiMeglio3, Lucy D Mastrandrea4, Kimber-Lee Abel5, Eda Cengiz6, Pinar A Cemeroglu7, Grazia Aleppo8, Joseph F Largay9, Nicole C Foster2, Roy W Beck2, Saleh Adi1. 1. 1 University of California, San Francisco, San Francisco, CA, USA. 2. 2 Jaeb Center for Health Research, Tampa, FL, USA. 3. 3 Indiana University School of Medicine, Indianapolis, IN, USA. 4. 4 University at Buffalo, School of Medicine, Buffalo, NY, USA. 5. 5 Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. 6 Yale School of Medicine, New Haven, CT, USA. 7. 7 Helon DeVos Children's Hospital, Grand Rapids, MI, USA. 8. 8 Northwestern University, Chicago, IL, USA. 9. 9 University of North Carolina, Chapel Hill, NC, USA.
Abstract
BACKGROUND: The objectives of this study were to examine factors associated with insulin pump discontinuation among children and adults followed longitudinally for 1 year in the multicenter T1D Exchange clinic registry, and to provide participant-reported reasons for stopping pump therapy. METHODS: We longitudinally followed 8935 participants of all ages using an insulin pump at the time of registry enrollment. Logistic regressions were used to identify demographic and clinical factors associated with pump discontinuation. Pump discontinuation was self-reported by participants on a first annual follow-up survey. RESULTS: The overall frequency of pump discontinuation was 3%. Discontinuation was higher in adolescents (4%) and young adults (4%) than in younger children (3%) or older adults (1%). In multivariate analysis of children between 6 and <13 and 13 and <18 years, participants who discontinued pump use were more likely to have higher HbA1c levels at baseline (adjusted P < .001 for both). The top participant-reported reasons for discontinuing the pump included problems with wearability (57%), disliking the pump or feeling anxious (44%), and problems with glycemic control (30%). CONCLUSIONS: In T1D Exchange registry participants, insulin pump discontinuation is uncommon, but more prevalent among adolescents and young adults, and youth with poor glycemic control. Given the known benefits of pump therapy, these populations should be targeted for support and education on troubleshooting pump use. Common reasons for discontinuation should also be considered in future device design and technological improvement.
BACKGROUND: The objectives of this study were to examine factors associated with insulin pump discontinuation among children and adults followed longitudinally for 1 year in the multicenter T1D Exchange clinic registry, and to provide participant-reported reasons for stopping pump therapy. METHODS: We longitudinally followed 8935 participants of all ages using an insulin pump at the time of registry enrollment. Logistic regressions were used to identify demographic and clinical factors associated with pump discontinuation. Pump discontinuation was self-reported by participants on a first annual follow-up survey. RESULTS: The overall frequency of pump discontinuation was 3%. Discontinuation was higher in adolescents (4%) and young adults (4%) than in younger children (3%) or older adults (1%). In multivariate analysis of children between 6 and <13 and 13 and <18 years, participants who discontinued pump use were more likely to have higher HbA1c levels at baseline (adjusted P < .001 for both). The top participant-reported reasons for discontinuing the pump included problems with wearability (57%), disliking the pump or feeling anxious (44%), and problems with glycemic control (30%). CONCLUSIONS: In T1D Exchange registry participants, insulin pump discontinuation is uncommon, but more prevalent among adolescents and young adults, and youth with poor glycemic control. Given the known benefits of pump therapy, these populations should be targeted for support and education on troubleshooting pump use. Common reasons for discontinuation should also be considered in future device design and technological improvement.
Authors: Hsin-Chieh Yeh; Todd T Brown; Nisa Maruthur; Padmini Ranasinghe; Zackary Berger; Yong D Suh; Lisa M Wilson; Elisabeth B Haberl; Jessica Brick; Eric B Bass; Sherita Hill Golden Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Jamie R Wood; Elaine C Moreland; Lisa K Volkening; Britta M Svoren; Deborah A Butler; Lori M B Laffel Journal: Diabetes Care Date: 2006-11 Impact factor: 19.112
Authors: Roy W Beck; William V Tamborlane; Richard M Bergenstal; Kellee M Miller; Stephanie N DuBose; Callyn A Hall Journal: J Clin Endocrinol Metab Date: 2012-09-20 Impact factor: 5.958
Authors: Kevin T Nguyen; Nicole Y Xu; Bruce A Buckingham; Sarnath Chattaraj; Ohad Cohen; Lutz Heinemann; John Pickup; Jannet Svensson; Robert A Vigersky; Jenise C Wong; Ralph Ziegler Journal: J Diabetes Sci Technol Date: 2022-02-28
Authors: Daniel P Howsmon; Nihat Baysal; Bruce A Buckingham; Gregory P Forlenza; Trang T Ly; David M Maahs; Tatiana Marcal; Lindsey Towers; Eric Mauritzen; Sunil Deshpande; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; Eyal Dassau; Juergen Hahn; B Wayne Bequette Journal: J Diabetes Sci Technol Date: 2018-02-01
Authors: Gregory P Forlenza; Laurel H Messer; Cari Berget; R Paul Wadwa; Kimberly A Driscoll Journal: Curr Diab Rep Date: 2018-09-26 Impact factor: 4.810
Authors: J Weissberg-Benchell; J B Shapiro; K Hood; L M Laffel; D Naranjo; K Miller; K Barnard Journal: Diabet Med Date: 2019-03-20 Impact factor: 4.359
Authors: Yun Jeong Lee; Young Ah Lee; Jae Hyun Kim; Hye Rim Chung; Min Jeong Gu; Ji Young Kim; Choong Ho Shin Journal: Ann Pediatr Endocrinol Metab Date: 2020-12-31
Authors: Sarah K Lyons; Osagie Ebekozien; Ashley Garrity; Don Buckingham; Ori Odugbesan; Sarah Thomas; Nicole Rioles; Kathryn Gallagher; Rona Y Sonabend; Ilona Lorincz; G Todd Alonso; Manmohan K Kamboj; Joyce M Lee Journal: Clin Diabetes Date: 2021-07